Structure Therapeutics American Stock Number Of Employees
| GPCR Stock | 35.99 0.17 0.47% |
Structure Therapeutics American fundamentals help investors to digest information that contributes to Structure Therapeutics' financial success or failures. It also enables traders to predict the movement of Structure Stock. The fundamental analysis module provides a way to measure Structure Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Structure Therapeutics stock.
Structure | Number Of Employees |
Structure Therapeutics American Company Number Of Employees Analysis
Structure Therapeutics' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Structure Therapeutics Number Of Employees | 93 |
Most of Structure Therapeutics' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Structure Therapeutics American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Structure Number Of Employees Driver Correlations
Understanding the fundamental principles of building solid financial models for Structure Therapeutics is extremely important. It helps to project a fair market value of Structure Stock properly, considering its historical fundamentals such as Number Of Employees. Since Structure Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Structure Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Structure Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Structure Therapeutics American is currently employing 93 people. This is 99.15% lower than that of the Biotechnology sector and 82.63% lower than that of the Health Care industry. The number of employees for all United States stocks is 99.51% higher than that of the company.
Structure Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Structure Therapeutics' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Structure Therapeutics could also be used in its relative valuation, which is a method of valuing Structure Therapeutics by comparing valuation metrics of similar companies.Structure Therapeutics is currently under evaluation in number of employees category among related companies.
Structure Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Structure Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Structure Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Structure Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 4.55 B | ||||
| Shares Outstanding | 46.62 M | ||||
| Shares Owned By Insiders | 6.76 % | ||||
| Shares Owned By Institutions | 96.38 % | ||||
| Number Of Shares Shorted | 4.29 M | ||||
| Price To Book | 4.04 X | ||||
| EBITDA | (101.74 M) | ||||
| Net Income | (89.54 M) | ||||
| Total Debt | 5.45 M | ||||
| Book Value Per Share | 9.76 X | ||||
| Cash Flow From Operations | (79.42 M) | ||||
| Short Ratio | 9.62 X | ||||
| Earnings Per Share | (2.43) X | ||||
| Target Price | 76.89 | ||||
| Number Of Employees | 93 | ||||
| Market Capitalization | 1.67 B | ||||
| Total Asset | 482.02 M | ||||
| Retained Earnings | (206.57 M) | ||||
| Working Capital | 448.87 M | ||||
| Net Asset | 482.02 M |
About Structure Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Structure Therapeutics American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Structure Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Structure Therapeutics American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Structure Therapeutics Piotroski F Score and Structure Therapeutics Altman Z Score analysis. Note that the Structure Therapeutics information on this page should be used as a complementary analysis to other Structure Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Structure Stock analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Structure Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.